Submitted 10 May 2016; accepted in final form 1 June 2016 TO THE EDITOR: We have serious concerns regarding the recently published paper by Singh et al. (16) , which states, "Our work has important general implications that should hopefully lead to questioning of many current trends or practices including use of inhaled insulin formulations in diabetes." This conclusion is not supported as evidenced by 1) the technical limitations in the experiments described in the paper and 2) the omission of abundant pertinent data that is neither referenced nor discussed. The pulmonary effects of inhaled insulin in both patients and animals have been well described in the literature and show minimal effects. These peer-reviewed papers are absent in the Singh paper. In summary, this paper applies poorly designed experiments in mice to humans, ignoring decades of relevant research. Below, we detail the major deficiencies. Importantly, we believe it is irresponsible to use the data in the Singh et al. paper as the foundation for giving advice to physicians and their patients.
Technical Limitations
The focus of this paper is the possible pulmonary effects of insulin delivered to the lungs. However, the method used in this paper is an inefficient and imprecise way of achieving pulmonary dosing. They do not use inhalation, and they don't even use intratracheal instillation (IT). Many labs, including that of one of us [Brain et al. (1) ] routinely employ intratracheal instillations in 20-g mice. With nasal instillation as is used in the experiments reported by Singh et al. (16) , little of the instilled material may get into the lungs when volumes are small. As the volume of the instilled solution increases, an increasing but variable fraction is aspirated into the lungs (17) . In this paper, no information is given that tells us the fraction of the intranasal dose that actually reaches the lungs. They also fail to tell us the instilled volume. The fact that the insulin dose was very high and the animals did not die of hypoglycemia suggests that much of the "delivered dose" was probably swallowed and digested.
The anatomic distribution of particles in the lungs differs following instillation vs. inhalation. It is important to recognize that the liquid solution used to deliver the insulin was an acid, pH 2 (0.01 N HCl). Not only is insulin unstable at this pH but the major acidic degradation products, covalent dimers, are the most immunogenic degradation products from insulin. More importantly, acid aerosols of pH 2 have been clearly shown to have adverse effects in both humans (8) and animals (14) . Respiratory complications of gastroesophageal reflux are well known and may have influenced results. Use of this inappropriate vehicle may have influenced the results. In addition, 0.01 N HCl is hypotonic. Hypotonic solutions can cause damage and bursting of epithelial cells. Instillations should always be isotonic.
Essential controls are missing from the experimental design. The "controls" they describe are animals that were given the vehicle, 0.01 normal hydrochloric acid (pH 2). We believe that 11 daily sequential anesthesias and instillations of acid into the nose, pharynx, and lungs had effects on both of the two groups studied. Conspicuous by its absence is a necessary third group, a true control. We regard this omission of animals that received neither of these two treatments as a serious flaw. They compare the acid vehicle only with the vehicle plus insulin. We suspect that these repeated nasal instillations affected the entire physiology of the mice. For example, what were the changes in body weight over the study period? We predict that this harsh treatment would result in loss of body weight, but we don't know since there is no true control.
The histopathology as presented in the paper is very difficult to interpret and the interpretations are of concern based on the following comments.
• The MATERIALS AND METHODS does not provide adequate description of the methods used for fixation of the lungs, which is critical when trying to make statements about changes in lung structure. We had to go back through two references to any mention on the protocols used for fixation and even then the description is minimal. When defining changes to lung structure it would be hoped that the authors would follow the guidelines set out by the ATS for fixation of lung tissue [Hsia CC et al., ATS/ERS Joint Task Force on Quantitative Assessment of Lung Structure (5)].
• There is not a quantitative nor semiquantitative evaluation of the lesions presented. With the advances in digital imaging and imaging software one would expect that some type of quantitative analysis be performed to remove bias from the data present. There are concerns over the data presented due to the following observations of the work presented in this manuscript: 1) The photos are of such a low power that they cannot be evaluated from the publication and descriptions or observations are vaguely described. For instance a PAS stain is provided to show goblet cells, however, Alcian blue-should also have been used.
2) There is a claim of peribronchial collagen production, but appearance of true collagen in 12 days seems unrealistic.
3) The presence of smooth muscle in the normal mouse lung is to be expected and depends on what areas of the lung are sampled (18) . Also nonuniform distribution of insulin from the instillation procedure could have influenced results. Therefore, the authors would need to perform uniform random sampling of the lungs and images acquired to accurately interpret findings from these studies. The importance of performing adequate sampling of airways for inhaled toxicants is provided by Dallas Hyde et al. (6) .
4) Tissue quantitation can be influenced heavily by what parts of the lung are examined since if too much of the upper airway or mediastinum is included native collagen levels can skew measurements.
• Selective histological examination can compromise outcomes and the lack of an appropriate control group can make interpretation uncertain. The ␤-catenin knockdown data are also difficult to interpret. Singh et al. (16) do not describe the carrier system used to deliver the siRNA. This is problematic since most of these carriers (typically lipids) are associated with enhancing siRNA-mediated innate inflammatory, which can confound findings and must be appropriately controlled (10) . The dose of insulin used, 50 g, is high and of limited relevance to human clinical use. The 50-g dose in a mouse of typical body weight of 25 g is 2 g/g, or 2 mg/kg. This dose is approximately threefold higher than the deposited lung dose of 0.6 mg/kg insulin that was found to be without effects on lung histopathology following 6 mo of inhalation exposure in rats (2) . It is also 13-fold higher than the 0.15 mg/kg insulin lung dose estimated for mean human use for Exubera (2) . The 0.15 mg/kg dose is the nominal capsule dose delivered to humans, while the lung deposited dose is ϳ0.05-0.07 mg/kg or 30-to 40-fold less than the mouse lung dose. Thus the Singh experiments are at doses that would not be achieved in human use. Rodents metabolize insulin more quickly than humans and so much higher lung doses can be achieved in rodents compared with humans. We also note the absence of any information about the grade of the Sigma human recombinant insulin used.
Pertinent Animal and Human Data
The paper by Singh et al. (16) omits reference to the considerable body of information relating to the pulmonary safety of inhaled insulin in patients and animals. Extensive clinical data with inhaled insulin provides the most relevant information. Pfizer's inhaled insulin product (Exubera) was approved by both the FDA and the EU. This was based on more than a decade of experiments and studies of thousands of patients. Bronchopulmonary lavage after 3 mo of inhaled prandial insulin showed no inflammatory markers (7) in the face of measured higher levels of insulin (9) . Eli Lilly and Novo Nordisk also have extensive clinical experience similar to that of Exubera (15) . Finally, more recently, Mannkind's inhaled insulin (Afrezza) was approved by the FDA and it is currently being marketed. For both approved drugs large amounts of data were submitted, reviewed, and formed the basis of a positive FDA decision.
The review paper by Siekmeier and Scheuch (15) lists results from 20 clinical trials that studied the safety of inhaled insulin. In none of the studies were there any findings of clinical significance. In one of the largest trials, a 2-year study of Exubera (13), it was stated that "Small, clinically nonmeaningful treatment group differences in the change in FEV1 during the first 3 mo of treatment were found. Most notably, the between-group differences did not increase after 3 mo for up to 2 years, and pulmonary function declined at similar rates in both groups during months 3 to 24." Additional clinical information has also become available since the Siekmeier and Scheuch (15) review primarily on Afrezza with similar results (11) . The only clinically relevant negative pulmonary finding in patients has been bronchospasm in individuals with asthma/ COPD with Afrezza (3), which appears to be related to the fumaryl diketopiperazine excipient specific to the Afrezza formulation. Also, Singh et al. (16) reported data suggesting an increase in airway hyperresponsiveness in rats, whereas clinical data with another inhaled growth factor promoter, human growth hormone, showed no change in airway hyperresponsiveness in individuals with asthma (10).
Singh et al. (16) also failed to refer to the information from long-term 6-mo toxicity studies of inhaled insulin in rats and monkeys (2) and in dogs (19) at lung deposited doses of 0.6 mg/kg, 0.15 mg/kg, and 0.18 mg/kg, the maximum tolerated doses in these respective species. All of these studies conducted using the appropriate administration method of inhalation delivery showed no effects on pulmonary function or lung histopathology.
The study reported by Singh et al. has many technical limitations and was conducted at doses not relevant to human inhalation delivery. These facts should be considered as well as the overwhelming clinical evidence at relevant doses and the appropriate inhalation delivery route that shows inhaled insulin poses minimal risks to patients with diabetes while offering the possibility that patient preference for inhalation translates to better compliance and improved outcomes. 
